News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
Events Partner Content STING & TLR Targeting Therapies Summit Investigating the cGAS-STING and TLR pathways
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
